Dr. Christopher B. Benton, M.D.
Hematology & Oncology (Hematology & Oncology Physician)
701 E Hampden Ave Ste 300
Englewood, CO 80113
Who else practices at this address →
Arapahoe County includes primary care (8% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Medical school
- Baylor College of Medicine (2005)
- Years since graduation
- 21
- In the NPI registry since
- 2009
- Medicare patients seen, 2024
- 665
Licensed in Texas since 2010, according to the Texas Medical Board. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2005Medical school: Baylor College of Medicine
- 2009Registered with an NPI (national billing number; not a license date)
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology & Oncology Physician primary
CO license DR.0062478 (first issued 2019; active) -
Internal Medicine Physician
TX license BP10023108 · TX license N5566 (first issued 2010; canc non-renewal)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Adventhealth Littleton Littleton, CO
- Hca-Healthone DBA Swedish Medical Center Englewood, CO
- The Medical Center of Aurora & South Hospital Aurora, CO
Medical groups
- Rocky Mountain Cancer Centers LLP (132 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 665
- Services billed
- 174,457
- Patients’ average age
- 74
| Service | Times | Patients |
|---|---|---|
| Injection, darbepoetin alfa, 1 microgram (non-esrd use) | 35,085 | 30 |
| Injection, luspatercept-aamt, 0.25 mg | 21,400 | 11 |
| Injection, iron sucrose, 1 mg | 20,700 | 40 |
| Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | 16,320 | 21 |
| Injection, filgrastim-sndz, biosimilar, (zarxio), 1 microgram | 13,320 | 18 |
| Injection, pembrolizumab, 1 mg | 12,400 | 18 |
| Injection, fosaprepitant, 1 mg | 11,250 | 30 |
| Injection, azacitidine, 1 mg | 6,400 | 11 |
| Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units | 3,340 | 12 |
| Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg | 2,460 | 11 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Jakafi (ruxolitinib phosphate) | 343 |
| Warfarin Sodium Other prescribers in Englewood, CO | 189 |
| Eliquis (apixaban) Other prescribers in Englewood, CO | 187 |
| Xarelto (rivaroxaban) Other prescribers in Englewood, CO | 169 |
| Valacyclovir (valacyclovir hcl) Other prescribers in Englewood, CO | 106 |
| Hydroxyurea Other prescribers in Englewood, CO | 79 |
| Revlimid (lenalidomide) | 60 |
| Ojjaara (momelotinib dihydrochloride) | 58 |
| Venclexta (venetoclax) | 52 |
| Inqovi (decitabine/cedazuridine) | 43 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 22 companies reported 112 payments worth $118,372 in total to this clinician.
| E.r. Squibb & Sons, L.l.c. | $28,679 |
|---|---|
| GlaxoSmithKline, LLC. | $16,697 |
| Geron Corporation | $12,877 |
| Sobi, Inc | $12,227 |
| Alexion Pharmaceuticals, Inc. | $10,556 |
| Novartis Pharmaceuticals Corporation | $10,541 |
| Incyte Corporation | $9,456 |
| Syndax Pharmaceuticals, Inc. | $8,963 |
| Compensation for services other than consulting (speaking, faculty) | $62,622 |
|---|---|
| Consulting Fee | $47,662 |
| Travel and Lodging | $5,208 |
| Food and Beverage | $2,880 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Alexion Pharmaceuticals, Inc. May 8, 2025 | Consulting Fee | $9,920 |
| E.r. Squibb & Sons, L.l.c. Jan 24, 2025 | Consulting Fee | $7,640 |
| Geron Corporation Mar 12, 2025 | Compensation for services other than consulting (speaking, faculty) RYTELO · MYELODYSPLASTIC SYNDROME | $5,760 |
| E.r. Squibb & Sons, L.l.c. Sep 4, 2025 | Compensation for services other than consulting (speaking, faculty) REBLOZYL · Hematology | $5,460 |
| E.r. Squibb & Sons, L.l.c. May 1, 2025 | Compensation for services other than consulting (speaking, faculty) REBLOZYL · Hematology | $4,550 |
| Novartis Pharmaceuticals Corporation May 29, 2025 | Consulting Fee | $4,200 |
| Geron Corporation Oct 22, 2025 | Compensation for services other than consulting (speaking, faculty) RYTELO · MYELODYSPLASTIC SYNDROME | $4,160 |
| Sobi, Inc Jul 24, 2025 | Compensation for services other than consulting (speaking, faculty) Vonjo · Hematology/Oncology | $3,850 |
| Sobi, Inc Oct 30, 2025 | Compensation for services other than consulting (speaking, faculty) Vonjo · Hematology/Oncology | $3,850 |
| E.r. Squibb & Sons, L.l.c. May 5, 2025 | Compensation for services other than consulting (speaking, faculty) REBLOZYL · Hematology | $3,640 |
All 56 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| GlaxoSmithKline, LLC. Dec 4, 2025 | Compensation for services other than consulting (speaking, faculty) OJJAARA · ONCOLOGY | $1,088 |
| Incyte Corporation Nov 11, 2025 | Compensation for services other than consulting (speaking, faculty) Jakafi · Hematology/Oncology | $2,740 |
| Sobi, Inc Oct 30, 2025 | Compensation for services other than consulting (speaking, faculty) Vonjo · Hematology/Oncology | $3,850 |
| Geron Corporation Oct 22, 2025 | Compensation for services other than consulting (speaking, faculty) RYTELO · MYELODYSPLASTIC SYNDROME | $4,160 |
| GlaxoSmithKline, LLC. Oct 17, 2025 | Compensation for services other than consulting (speaking, faculty) OJJAARA · ONCOLOGY | $1,450 |
| GlaxoSmithKline, LLC. Oct 8, 2025 | Compensation for services other than consulting (speaking, faculty) OJJAARA · ONCOLOGY | $2,900 |
| GlaxoSmithKline, LLC. Oct 2, 2025 | Travel and Lodging OJJAARA · ONCOLOGY · travel to Albuquerque, NM · in-kind | $482 |
| GlaxoSmithKline, LLC. Oct 2, 2025 | Travel and Lodging OJJAARA · ONCOLOGY · travel to Albuquerque, NM · in-kind | $299 |
| Incyte Corporation Oct 1, 2025 | Compensation for services other than consulting (speaking, faculty) Jakafi · Hematology/Oncology | $2,055 |
| Sobi, Inc Sep 25, 2025 | Compensation for services other than consulting (speaking, faculty) | $3,080 |
| Geron Corporation Sep 25, 2025 | Travel and Lodging RYTELO · MYELODYSPLASTIC SYNDROME · travel to COLORADO SPRINGS, CO · in-kind | $1,054 |
| Incyte Corporation Sep 24, 2025 | Compensation for services other than consulting (speaking, faculty) Jakafi · Hematology/Oncology | $2,055 |
| E.r. Squibb & Sons, L.l.c. Sep 4, 2025 | Compensation for services other than consulting (speaking, faculty) REBLOZYL · Hematology | $5,460 |
| AbbVie Inc. Sep 4, 2025 | Consulting Fee VENCLEXTA · ONCOLOGY | $525 |
| E.r. Squibb & Sons, L.l.c. Sep 2, 2025 | Consulting Fee | $955 |
| E.r. Squibb & Sons, L.l.c. Aug 21, 2025 | Travel and Lodging REBLOZYL · Hematology · travel to Pueblo, CO | $761 |
| Syndax Pharmaceuticals, Inc. Aug 16, 2025 | Consulting Fee REVUFORJ · HEMATOLOGY-ONCOLOGY | $3,475 |
| Syndax Pharmaceuticals, Inc. Aug 16, 2025 | Travel and Lodging REVUFORJ · HEMATOLOGY-ONCOLOGY · travel to SCOTTSDALE, AZ · in-kind | $282 |
| Syndax Pharmaceuticals, Inc. Aug 16, 2025 | Travel and Lodging REVUFORJ · HEMATOLOGY-ONCOLOGY · travel to SCOTTSDALE, AZ · in-kind | $141 |
| Syndax Pharmaceuticals, Inc. Aug 16, 2025 | Travel and Lodging REVUFORJ · HEMATOLOGY-ONCOLOGY · travel to SCOTTSDALE, AZ · in-kind | $41.51 |
| Syndax Pharmaceuticals, Inc. Jul 25, 2025 | Compensation for services other than consulting (speaking, faculty) REVUFORJ · HEMATOLOGY-ONCOLOGY Company’s descriptionBranded Speaker Training | $900 |
| Sobi, Inc Jul 24, 2025 | Compensation for services other than consulting (speaking, faculty) Vonjo · Hematology/Oncology | $3,850 |
| Novartis Pharmaceuticals Corporation Jul 17, 2025 | Consulting Fee SCEMBLIX · Oncology | $1,400 |
| Genzyme Corporation Jul 15, 2025 | Consulting Fee | $3,360 |
| Novartis Pharmaceuticals Corporation Jul 14, 2025 | Consulting Fee SCEMBLIX · Oncology | $1,400 |
| Novartis Pharmaceuticals Corporation Jun 27, 2025 | Consulting Fee | $2,800 |
| GlaxoSmithKline, LLC. Jun 17, 2025 | Compensation for services other than consulting (speaking, faculty) OJJAARA · ONCOLOGY | $2,900 |
| GlaxoSmithKline, LLC. Jun 10, 2025 | Compensation for services other than consulting (speaking, faculty) OJJAARA · ONCOLOGY | $2,900 |
| Incyte Corporation Jun 10, 2025 | Compensation for services other than consulting (speaking, faculty) Jakafi · Hematology/Oncology | $2,055 |
| Incyte Corporation Jun 6, 2025 | Compensation for services other than consulting (speaking, faculty) Jakafi · Hematology/Oncology | $343 |
| Novartis Pharmaceuticals Corporation May 29, 2025 | Consulting Fee | $4,200 |
| Sobi, Inc May 22, 2025 | Consulting Fee Vonjo · Hematology/Oncology | $1,155 |
| E.r. Squibb & Sons, L.l.c. May 15, 2025 | Consulting Fee | $1,194 |
| Alexion Pharmaceuticals, Inc. May 8, 2025 | Consulting Fee | $9,920 |
| Syndax Pharmaceuticals, Inc. May 6, 2025 | Compensation for services other than consulting (speaking, faculty) | $1,500 |
| E.r. Squibb & Sons, L.l.c. May 5, 2025 | Compensation for services other than consulting (speaking, faculty) REBLOZYL · Hematology | $3,640 |
| E.r. Squibb & Sons, L.l.c. May 1, 2025 | Compensation for services other than consulting (speaking, faculty) REBLOZYL · Hematology | $4,550 |
| Alexion Pharmaceuticals, Inc. Apr 25, 2025 | Travel and Lodging travel to Tamoa, FL · in-kind Company’s descriptionConsulting Expenses | $309 |
| Alexion Pharmaceuticals, Inc. Apr 25, 2025 | Travel and Lodging travel to Denver, CO Company’s descriptionConsulting Expenses | $58.00 |
| Alexion Pharmaceuticals, Inc. Apr 25, 2025 | Travel and Lodging travel to Tampa, FL · in-kind Company’s descriptionConsulting Expenses | $43.42 |
| GlaxoSmithKline, LLC. Apr 7, 2025 | Consulting Fee OJJAARA · ONCOLOGY | $2,800 |
| Taiho Oncology, Inc. Mar 19, 2025 | Consulting Fee INQOVI · Oncology | $2,100 |
| Geron Corporation Mar 12, 2025 | Compensation for services other than consulting (speaking, faculty) RYTELO · MYELODYSPLASTIC SYNDROME | $5,760 |
| AbbVie Inc. Mar 6, 2025 | Consulting Fee VENCLEXTA · ONCOLOGY | $600 |
| GlaxoSmithKline, LLC. Feb 28, 2025 | Compensation for services other than consulting (speaking, faculty) OJJAARA · ONCOLOGY | $1,452 |
| E.r. Squibb & Sons, L.l.c. Feb 25, 2025 | Compensation for services other than consulting (speaking, faculty) REBLOZYL · Hematology | $3,185 |
| Amgen Inc. Feb 21, 2025 | Compensation for services other than consulting (speaking, faculty) BLINCYTO · Oncology | $750 |
| Geron Corporation Feb 6, 2025 | Travel and Lodging RYTELO · MYELODYSPLASTIC SYNDROME · travel to TUCSON, AZ · in-kind | $835 |
| Geron Corporation Feb 6, 2025 | Travel and Lodging RYTELO · MYELODYSPLASTIC SYNDROME · travel to TUCSON, AZ · in-kind | $384 |
| Geron Corporation Feb 6, 2025 | Travel and Lodging RYTELO · MYELODYSPLASTIC SYNDROME · travel to TUCSON, AZ · in-kind | $279 |
| Geron Corporation Feb 6, 2025 | Travel and Lodging RYTELO · MYELODYSPLASTIC SYNDROME · travel to TUCSON, AZ · in-kind | $239 |
| Syndax Pharmaceuticals, Inc. Jan 31, 2025 | Consulting Fee | $1,200 |
| E.r. Squibb & Sons, L.l.c. Jan 24, 2025 | Consulting Fee | $7,640 |
| E.r. Squibb & Sons, L.l.c. Jan 24, 2025 | Consulting Fee | $1,038 |
| Syndax Pharmaceuticals, Inc. Jan 13, 2025 | Consulting Fee | $1,200 |
| Novartis Pharmaceuticals Corporation Jan 1, 2025 | Consulting Fee SCEMBLIX · Oncology | $700 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 4 industry-funded studies in 2025, from 3 companies. The companies reported $212,196 in research payments for these studies, mostly to the institutions running them.
- A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis
Karyopharm Therapeutics Inc. - A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate Efficacy and Safety of Mezagitamab Subcutaneous Injection in Participants with Chronic Primary Immune Thrombocytopenia
Takeda Pharmaceuticals U.S.A., Inc. - A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound KPT-8602 in Patients with Relapsed, Refractory Cancer Indications
Karyopharm Therapeutics Inc. - Study name not reported
Pharmaessentia USA Corporation
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.